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Significance Statement 
Extracellular calcium modulates calciuria by acting on the basolateral membrane calcium-
sensing receptor (CaSR) of the thick ascending limb of Henle’s loop (TALH), reducing calcium 
reabsorption at the expense of apical salt absorption. CaSR is also expressed in the apical 
membrane of the distal convoluted tubule. Here we show using in vitro and in vivo models, that 
stimulation of the CaSR induces activation of the Na-Cl cotransporter (NCC), by a pathway that 
involves a PKC-induced activation of the KELCH3-WNK4-SPAK pathway that ultimately 
phosphorylates NCC, increasing its activity. This study proposes a mechanism through which 
salt reabsorption is upregulated beyond the TALH to recover the salt, while calcium is excreted. 
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Abstract 
Extracellular Ca
2+
 inhibits NaCl reabsorption in the thick ascending limb of Henle’s loop 
(TALH) through the basolateral Calcium-sensing Receptor (CaSR) to induce hypercalciuria. 
CaSR is also expressed in the apical membrane of the distal convoluted tubule (DCT), were 
we hypothesized that it could play a role in activating NCC via the WNK4-SPAK pathway to 
prevent NaCl loss. Here we demonstrate, using a combination of in vitro and in vivo models 
that activation of CaSR leads to phosphorylation and concomitant activation of NCC. First, 
functional expression of NCC (thiazide-sensitive 
22
Na
+
 uptake) was assessed in Xenopus laevis
oocytes where we found that NCC activity was increased in a WNK4-dependent manner 
when CaSR was activated with gadolinium. Second, in HEK293 cells, the calcimimetic R-568 
stimulated SPAK phosphorylation only in the presence of WNK4. WNK4 inhibitor, WNK463, 
also prevented this effect. Furthermore, we found that CaSR activation leads to KLHL3 and 
WNK4 phosphorylation and consequently, increased WNK4 abundance and activity. Lastly, 
mice administered with R-568 showed NCC phosphorylation. Our results show that 
activation of CaSR can increase NCC activity via the WNK4-SPAK pathway. It is possible that 
activation of CaSR by Ca
2+ 
in the apical membrane of DCT increases NaCl reabsorption via 
NCC, with the consequent well known decrease of calcium reabsorption, further promoting 
hypercalciuria. 
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Significance Statement 
Extracellular calcium modulates calciuria by acting on the basolateral membrane calcium-
sensing receptor (CaSR) of the thick ascending limb of Henle’s loop (TALH), reducing calcium 
reabsorption at the expense of apical salt absorption. CaSR is also expressed in the apical 
membrane of the distal convoluted tubule. Here we show using in vitro and in vivo models, 
that stimulation of the CaSR induces activation of the Na-Cl cotransporter (NCC), by a 
pathway that involves a PKC-induced activation of the KELCH3-WNK4-SPAK pathway that 
ultimately phosphorylates NCC, increasing its activity. This study proposes a mechanism 
through which salt reabsorption is upregulated beyond the TALH to recover the salt, while 
calcium is excreted. 
Page 4 of 46
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4
Introduction 
The calcium-sensing receptor (CaSR) is a member of class C of the G-protein coupled 
receptors (GPCR) and its role is to constantly monitor Ca
2+
 in the extracellular environment
1
. 
In the kidney, CaSR is essential for sensing Ca
2+
 in both the urinary filtrate and interstitial 
fluid to adequately modulate calcium excretion. To achieve this, CaSR is expressed all along 
the nephron
2-5
. 
Ca
2+
 and salt (NaCl) handling in the kidney are particularly integrated in two segments of the 
nephron: the thick ascending limb of Henle’s loop (TALH) and the distal convoluted tubule 
(DCT). In the TALH Ca
2+ 
is reabsorbed by a paracellular route, a process which is largely 
dependent on NaCl reabsorption
6,7
. Apical NaCl influx via the Na
+
-K
+
-2Cl
-
 cotransporter 
(NKCC2) is accompanied by potassium recycling to the lumen, through the apical renal outer 
medullary K
+
 channel (ROMK, KCNJ1), and by the basolateral extrusion of NaCl by the Na
+
/K
+
-
ATPase and the chloride channel (CLCNKB)
8
. The apical recycling of K
+ 
generates a 
transepithelial voltage difference providing a driving force that drags paracellular 
reabsorption of cations, amongst them, Ca
2+ 9
. Consequently, a positive correlation exists 
between NaCl and Ca
2+
 reabsorption in this nephron segment. For instance, patients with 
Bartter syndrome exhibit a salt loosing nephropathy and hypercalciuria
10
. Likewise, clinicians 
have taken advantage of this positive correlation phenomenon by using loop diuretics to 
treat hypercalcemia
11
.  
In the TALH, CaSR is expressed in the basolateral membrane
2,5
 where it senses increased 
interstitial Ca
2+
 and promotes its urinary excretion by halting NKCC2 and ROMK activity
4,12-15
. 
In this manner, the increase in Ca
2+
 excretion is due to decreased NaCl reabsorption in the 
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TALH that must be reabsorbed beyond the macula densa. Indeed, gain-of-function mutations 
of CaSR have been reported to produce a Bartter-like syndrome
16,17
.
The DCT reabsorbs approximately 5-10% of the filtered NaCl and Ca
2+ 6,7,18
. Its impact on 
blood pressure and Ca
2+
 excretion is prominent since NaCl reabsorption beyond the macula 
densa is not regulated by tubuloglomerular feedback and no specific Ca
2+
 reabsorption 
pathways are present beyond this point
7
. In the DCT, reabsorption of NaCl occurs through 
the thiazide sensitive Na
+
-Cl
-
 cotransporter (NCC), whereas that of Ca
2+ 
through the apical 
transient receptor potential cation channel subfamily V (TRPV5)
18
. In this part of the 
nephron, NaCl and Ca
2+
 transport occurs in opposite directions; increased NaCl reabsorption 
is associated with decreased Ca
2+
 reabsorption
19
. For instance, patients with Gitelman 
syndrome present a salt losing nephropathy accompanied by hypocalciuria
20
. Clinicians have 
taken advantage of this by using thiazide diuretics to promote Ca
2+ 
reabsorption in patients 
with urolithiasis 
21
. The exact mechanism for this inverse relationship is still unclear. CaSR is 
expressed both in the basolateral and apical membranes of DCT cells
4,5,22
. However, the role 
CaSR might play in regulating NaCl reabsorption in this nephron segment is not known. 
The activity of NCC is modulated by a kinase pathway consisting of the with-no-lysine-
kinases (WNKs) acting upon the Ste20-related proline alanine-rich kinase (SPAK)
23
. Active 
WNK kinases phosphorylate SPAK
24
, which subsequently phosphorylates and activates 
NCC
25
. Two proteins, Cullin 3 (CUL3) and Kelch-like 3 (KLHL3), are part of a E3-RING ubiquitin 
ligase complex that in turn regulate WNK kinases. KLHL3 specifically binds to WNKs marking 
them for degradation
26,27
. Disease-causing mutations in WNK4, KLHL3 or CUL3 result in 
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impaired degradation of WNK kinases leading to increased NCC activity that results in a 
syndrome called Pseudohypoaldosteronism type II (PHAII)
 28,29
. 
Hormones that regulate NaCl reabsorption in the DCT do so by affecting the KLHL3-WNK-
SPAK-NCC pathway. Angiotensin II (AngII) regulates NCC activity in a WNK4-dependent 
manner
30,31
. This regulation occurs via protein kinase C (PKC), which directly phosphorylates 
WNK4 in two main sites, S64 and S1196, increasing WNK4 activity32. PKC also promotes 
phosphorylation of KLHL3 in a serine residue (S433) that lays in the WNK4-binding domain 
preventing degradation of WNK4
33
. The effects of AngII in the DCT are mediated by the AT1 
receptor, a pleiotropic GPCR whose intracellular signaling mechanisms are similar to that of 
CaSR
34
. Both receptors are preferentially coupled to Gaq and thus activate PLC transduction 
pathway increasing intracellular Ca
2+
 and activating PKC
14,35
. In the present work, using a 
combination of in vitro and in vivo approaches, we sought to test the hypothesis that 
activation of CaSR modulates NCC activity through the KLHL3-WNK4-SPAK pathway.  
Concise Methods 
In vitro Experiments  
To test the effects of CaSR on NCC activity in vitro we assessed NCC activity in Xenopus laevis
oocytes by measuring tracer 
22
Na
+
 uptake when CaSR was stimulated with gadolinium 
chloride (GdCl3), as described in complete methods (Supplemental Information, SI). In 
mammalian cells, the effect of CaSR activation was assessed in HEK-293 cells transiently 
transfected with CaSR wild-type (WT), CaSR mutants, WT mWNK4-HA, hSPAK-GFP-HA, 
with/without KELCH3 DNA and mWNK45A-HA mutant. Cells were stimulated with the 
calcimimetic NPS R-568 (Tocris Biosciences) and SPAK phosphorylation, as well WNK4 
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abundance and phosphorylation was assessed by Western blot analysis (Complete methods, 
SI).  
In vivo Experiments 
To test the effect of activating CaSR to KELCH3-WNK4SPAK-NCC pathway in vivo we used 
C57BL/6 male mice 12 to 16 weeks old exposed to vehicle or NPS R-568 (Tocris Biosciences) 
(3.0 µg/g of weight) by oral gavage
36,37
; or furosemide (Sigma) single IP dose of 15 mg/kg. 3 
h later kidneys were extracted, and proteins were prepared for Western blot (Complete 
methods, SI). We also used ex vivo kidney preparations such as the Langendorff system, as 
previously described
38,39
. Kidneys were perfused with vehicle or the calcimimetic, NPS R-
568, at a rate of 0.60 µg/ml/min for 30 min.  
Statistical Analysis 
Unpaired Student’s t test (two tailed) was used for comparison between two groups. One-
way ANOVA with Dunnett’s multiple comparison test was performed for comparison 
between multiple groups. p<0.05 was considered significant. Values are reported as mean ±
SEM. 
Results 
CaSR activates NCC in a WNK4-dependent manner in X. laevis oocytes 
Xenopus oocytes were co-injected with wild-type (WT) CaSR and NCC cRNA with or without 
WNK4 or WNK1 cRNA, and subjected to thiazide-sensitive tracer 
22
Na
+
 transport assays as 
previously reported
40
. Co-expressing NCC with WNK4 or WNK1 promoted a marked increase 
in basal NCC activity, 2- and 4-fold (p<0.001) respectively (Figure 1 A), as previously 
Page 8 of 46
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
8
described
41,42
. However, this increase was not affected by the presence of CaSR (Figure 1A). 
Thus, unstimulated CaSR by itself had no effect on NCC activity. We then tested the effect of 
CaSR stimulation in the absence or presence of WNK1 or WNK4 kinases. As Figure 1B shows, 
after exposing oocytes to the type 1 CaSR agonist, Gd
3+
, NCC uptake increased 2-fold 
(p<0.0001) only in oocytes co-expressing both CaSR and WNK4 (Figure 1B). We observed no 
effect of Gd
3+
 in oocytes injected with NCC+CaSR or NCC+WNK1+CaSR. These results suggest 
that, similarly to the effects of AngII
30,31
, WNK4 is required for the activation of CaSR to have 
an effect on NCC.
CaSR phosphorylates SPAK in a WNK4-dependent manner in HEK-293 cells 
To test whether the CaSR-NCC effect could also be observed in a human cell model, we 
analyzed the effects of activating CaSR on SPAK phosphorylation (pSPAK), as a surrogate of 
SPAK-NCC activation by WNKs in HEK-293 cells
24
. Cells were transiently transfected with 
SPAK-HA-GFP, WNK4-HA and CaSR and then treated with the calcimimetic NPS R-568 (R-
568)
43-45
. Results show that R-568 induced a time- and dose- dependent pSPAK increase in 
cells fasted in a serum-free medium (Supplemental Figure 2A and B). We next evaluated the 
role of WNK4 on SPAK phosphorylation by CaSR. HEK-293 cells were transfected with SPAK-
HA-GFP, CaSR and/or WNK4-HA. In cells transfected with CaSR alone, pSPAK did not increase 
after treatment with the calcimimetic. Only in the presence of CaSR and WNK4 together, the 
calcimimetic promoted a significant increase in pSPAK (p<0.05) (Figure 2A and B). To further 
test that WNK4 is required for translating CaSR activation to SPAK phosphorylation, we 
assessed the effect of the highly specific WNK inhibitor, WNK463
46
 on CaSR-induced SPAK 
phosphorylation. As shown in Figure 2C and D, the positive effect of R-568 on pSPAK was 
completely prevented by the presence of WNK463 inhibitor, confirming that in mammalian 
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9
cells the effect of CaSR is WNK4-dependent. It is known that CaSR activation leads to 
activation by phosphorylation of the mitogen-activated protein kinase ERK1,2
47
. Therefore, 
we analyzed ERK1,2 phosphorylation to verify CaSR activation in these experiments. As 
shown in Figure 2A, a clear functional activation of CaSR was achieved with R-568 in CaSR-
transfected cells, as demonstrated by increased ERK1,2 phosphorylation, but SPAK 
phosphorylation by CaSR only increases in the presence of WNK4. 
An activating mutation of CaSR increases WNK4 abundance 
Mutations in the CaSR gene result in Mendelian disorders characterized by altered Ca
2+
homeostasis
48
. Activating mutations of the receptor cause autosomal dominant 
hypocalcemia, while inactivating mutations cause dominant familial hypocalciuric 
hypercalcemia or recessive neonatal severe hyperparathyroidism
15,49,50
. We used two 
reported mutations, one activating, CaSR-E228K, and one inactivating, CaSR-R185Q, to 
assess their effects on the WNK4-SPAK-NCC pathway
51-53
. We transfected HEK-293 cells with 
the WT CaSR or the mutants with WNK4 and observed that CaSR-E228K increased WNK4 
abundance (Fig 3A and 3C). We reasoned that if CaSR was acting by the same signal 
transduction pathway as the AT1 receptor, the presence of KLHL3 would enhance this effect 
on WNK4. As expected, co-transfection of KLHL3 induced a significant decrease of WNK4 
abundance (Figure 3A and B) that was prevented by CaSR-E228K, but not by CaSR-R185Q, 
establishing a significant KLHL3-dependent increase in WNK4 total protein levels, only in the 
presence of the active mutant CaSR-E228K (Figure 3D). These results are consistent with the 
proposal that active CaSR may elicit the same signal transduction pathway as that of AT1R, 
resulting in decreased degradation of WNK4, likely due to inhibition of KLHL3
33
. 
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CaSR promotes KLHL3 and WNK4 phosphorylation by PKC 
Two previous studies have demonstrated that AngII effects on WNK4 are due to a Gq-PKC 
signaling transduction pathway
32,33
. To further determine whether CaSR activation elicited 
similar effects, we assessed if PKC phosphorylation of KLHL3 and WNK4 occurred after CaSR 
activation. KLHL3-Flag was immunoprecipitated from lysates of HEK-293 cells co-transfected 
with CaSR WT or CaSR mutants and subjected to immunoblotting with a monoclonal 
antibody that recognizes PKC phosphorylation site, pRRXS
32,33,54
. In the presence of the 
active mutant CaSR-E228K, KLHL3 pRRXS phosphorylation remarkably increased (p>0.01), 
while this was not observed with the inactive mutant CaSR-R185Q (Figure 4A). If PKC was 
responsible for these effects, we would expect that inhibition of PKC would prevent CaSR-
induced pRRXS increase in KLHL3. As shown in Fig 4B, bisindolylmaleimide I (BIM), used at a 
concentration considered to be a specific inhibitor of PKC
55
, significantly reduced KLHL3 
pRRXS phosphorylation. 
We next evaluated if CaSR-induced activation of PKC also promoted WNK4 phosphorylation. 
To this end we analyzed whether activating CaSR in HEK-293 cells with R-568 promoted 
phosphorylation of a key WNK4 PKC phosphorylation site, serine residue S1196
32
. Following 
transfection of WNK4-HA, SPAK-HA-GFP and CaSR, incubation with the calcimimetic resulted 
in a clear increase in S1196 phosphorylation (Fig 4C). Since the experiment was done with an 
acute CaSR activation of 30 min, no changes were seen in total WNK4 abundance, however, 
activation by phosphorylation of this site has been previously established, partially 
explaining why we can see an effect before WNK4 abundance increases. Furthermore, we 
used a WNK4 mutant that has all five serines of the PKC consensus sites (RRXS sites) mutated 
to alanines (WNK4-5A), which prevents PKC-induced phosphorylation
32
. The 5A mutation did 
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not alter WNK4 abundance, but remarkably reduced CaSR effect on SPAK phosphorylation 
(Figure 4D), suggesting that phosphorylation of these sites, and the consequent activation of 
WNK4 by PKC, is necessary for the complete effect of CaSR on the WNK4-SPAK pathway. 
CaSR promotes NCC phosphorylation in vivo
To define whether the CaSR effect on NCC occurred in vivo, we administered C57/BL6 male 
wild-type (WT) mice with an acute oral treatment of R-568 (3 µg/g of body weight)
 36,37
and 
3 h later, mice were euthanized to investigate the effects on NCC phosphorylation by 
immunoblotting. Calcimimetics directly target the TALH CaSR function
12
, thereby decreasing 
NKCC2 activity (hence, phosphorylation) and promoting increased luminal Ca
2+
 and NaCl 
delivery to the distal nephron
12
. To test if this effect occurred in our in vivo model we 
assessed NKCC2 phosphorylation after the administration of the calcimimetic. Figure 5A and 
B shows that mice treated with the calcimimetic exhibited a significant decrease of NKCC2 
phosphorylation.  
Activation of NCC is associated with increased phosphorylation of three residues, T55, T60 
and S73 in human NCC
25,56
, therefore, phosphorylation of any of these residues has been 
extensively used as surrogate of NCC activation
56
. As expected, treatment with the 
calcimimetic induced a 1.5-fold increase in NCC phosphorylation (p<0.05) (Figure 5C and D), 
without promoting changes in total NCC (NCC/b-actin 1.00 vs. 0.96531, p=NS). Moreover, in 
concordance with our in vitro data, activation of CaSR resulted in a significant increase in 
total WNK4 protein (1.7-fold increase, p<0.05) (Figure 5C and D). To evaluate if the increased 
WNK4 protein was activated by PKC, we analyzed the phosphorylation of residue S64, as 
previously reported
32
. We found that most of the WNK4 protein in the calcimimetic-
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administered group was phosphorylated in S64 (Figure 5C). However, the pS64/WNK4 ratio 
between vehicle and R-568 groups remained similar (pS64/WNK4 1.00 vs. 1.3050, p=NS). 
The absence of significance between the vehicle- and R-568- administered groups could be 
due to the concurrent increase in WNK4 protein. Additionally, immunofluorescence 
microscopy of kidneys extracted from wild-type mice showed increased membrane 
abundance after an acute dose of the calcimimetic (Figure 5E). Interestingly, the increase in 
NCC phosphorylation was not present in a knock-in mice in which SPAK cannot be activated 
by WNKs (mutation S243A)
57
 (pNCC/NCC 1.00 vs 0.99, p=NS) (Figure 5F and G).  
CaSR is expressed at both the apical and basolateral membranes of DCT cells. To investigate 
if increasing Ca
2+
 delivery to the DCT, and therefore, only activation of the apical CaSR is 
sufficient to elicit NCC phosphorylation, we administered C57/BL6 male WT mice with an 
acute treatment of furosemide (15 mg/kg over 3h), as previously described
58
. This specific 
dosage and short time of treatment has been described to increase Ca
2+
 and NaCl delivery to 
the DCT, without promoting dehydration
58
. No changes in plasma potassium after 3 h were 
observed (vehicle 4.3 ± 73 vs. furosemide 4.3 ± 0.25, p=NS). As expected, furosemide 
administration increased NCC phosphorylation 4-fold (p<0.05) while not increasing total NCC 
(NCC/b-actin 1.00 vs 0.9456, p=NS) (Figure 6A and B). In addition, furosemide administration 
was associated with increased WNK4 total protein and increased phosphorylation of WNK4 
at S64 (Figure 6C and D). Taken together, these results suggest that the acute inhibition of 
NKCC2 is associated with increased WNK4-NCC phosphorylation that was probably triggered 
by increased luminal Ca
2+
.  
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CaSR promotes NCC phosphorylation ex vivo
The administration of the calcimimetic in the previous experiments could have promoted 
NCC activation either by a direct effect on the kidney, through the mechanism proposed in 
our hypothesis, or by a secondary effect due to activation/modification of any of the 
multiple hormonal systems that can activate NCC
59
. Acute calcimimetic administration is 
associated with decreased activity of the renin-angiotensin II system
60,61
, making this 
possibility unlikely. Nevertheless, we studied NCC phosphorylation using an ex vivo system 
where intervention of the central nervous system and other extra renal hormonal systems 
are not expected to be present. Kidneys of WT male Wistar rats were perfused with 
physiological saline with vehicle or with R-568 (0.60 µg/ml/min). The concentration of R-568 
used in these experiments did not change the perfusion pressure, arguing against the 
presence of an intrarenal AngII effect. As shown in Figure 7 A and B, NCC and SPAK 
phosphorylation levels were significantly higher in kidneys perfused with the calcimimetic.  
Discussion 
In the present study, we show that CaSR activation is associated with increased NCC activity 
in vitro and in vivo. This increase involves PKC activation of the WNK4-SPAK pathway, 
supporting the hypothesis that CaSR modulates NCC activity. As previously shown for AngII, 
modulation of NCC via WNK4-SPAK occurs by two different pathways. Phosphorylation and 
concurrent activation of WNK4, and prevention of WNK4 degradation by KELCH3 
phosphorylation.  CaSR induced activation of NCC has an implication in the physiological 
response to increased extracellular Ca
2+
, which requires the kidney to promote its excretion 
at the apparent expense of reducing NaCl reabsorption in the TALH, thus increasing the 
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delivery of NaCl and Ca
2+
 to the distal nephron
14
. Integration of NaCl and Ca
2+
 homeostasis 
by CaSR in the DCT could prevent unwanted NaCl loss, while further permitting Ca
2+ 
excretion. In this regard, CaSR expression in the apical membrane of the DCT has been 
clearly established by many groups and recent studies co-localize CaSR with NCC in human 
and mouse kidneys
5,22
. Taking together the observations in this study, we propose the 
existence of a mechanism in the DCT, where apical CaSR responds to increased intratubular 
Ca
2+
 concentration evoking a CaSR-Gq-PKC-WNK4-SPAK signaling transduction pathway 
that promotes NCC activation to recover the NaCl that was not reabsorbed in the TALH, due 
to NKCC2 and ROMK inhibition (Fig 8). Because it is known that increased NaCl reabsorption 
in the DCT is associated with decreased Ca
2+
 absorption
14
, this mechanism not only claims 
the NaCl, but also further promotes hypercalciuria. The controversy of whether the thiazide 
effect on Ca
2+
 excretion occurs directly in the DCT or elsewhere
62,63
 does not contradict our 
findings.  
We are aware of the possibility that the basolateral CaSR in DCT may also elicit a response to 
activate NCC, and our results do not rule out this possibility. In this scenario, increased 
extracellular Ca
2+
 could simultaneously reduce NKCC2 activity in the TALH but increase NCC 
activity in the DCT, by activating the basolateral receptor in both segments. However, due to 
the presence of CaSR and NCC in the apical membrane, is it likely that luminal Ca
2+
 is also 
involved in this response. NCC activation elicited by a single acute dose of furosemide, 
known to promote increased Ca
2+
 delivery to DCT, supports the fact that activation of apical 
CaSR is enough to provoke the proposed response. It is also worth mentioning that patients 
with Autosomal Dominant Hypocalcemia (due to CaSR activating mutations) may exhibit a 
Bartter-like syndrome (also known as Bartter syndrome type V) that has been described as 
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mild in most patients
17,64,65
. Perhaps, CaSR activation in the DCT helps to reduce natriuresis, 
as compared with other types of Bartter syndrome.     
A similar mechanism prompted by CaSR in the nephron has been described before. It has 
been clinically recognized for many years that hypercalcemia induces polyuria
66,67
. 
Increasing urinary Ca
2+
 to the distal nephron could also promote precipitation of Ca
2+ 
and 
phosphate salts. Sands et al. elegantly demonstrated that apical CaSR in the collecting duct 
responds to increased luminal Ca
2+
 to blunt vasopressin-induced insertion of AQP-2 water 
channels into the apical membrane
68
. The latter would prevent water reabsorption in the 
collecting duct, allowing the urine to be diluted and thus preventing Ca
2+
 precipitation and 
formation of renal stones. The authors also demonstrated that the signaling pathway and 
molecular mechanisms initiated by CaSR was also by Gq and PKC proteins
68
. More recently, 
other groups have further established the association of active apical CaSR with decreased 
AQP2 abundance
69-71
. 
The observation that CaSR activation modulates NCC activity via WNK4-SPAK pathway may 
have further implications beyond the physiological mechanism of how NaCl is recovered in 
DCT when TALH NaCl reabsorption is decreased by Ca
2+
. First, it is known that arterial 
hypertension is highly prevalent in primary hyperparathyroidism, ranging from 40 to 65%, 
which is much higher than the expected 25 to 30% of hypertension in general adult 
population
72
. Given our observations, a possible mechanism could be that increased Ca
2+
 in 
the tubular fluid, as it occurs in hypercalcemia, stimulates the activity of NCC promoting NaCl 
reabsorption and hence, the development of hypertension. Second, it has been recently 
demonstrated that glucose and other sugars act as type II calcimimetics, enhancing CaSR 
Page 16 of 46
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
16
affinity for Ca
2+73
. This could be relevant in the apical membrane of the DCT since all the 
filtered glucose is reabsorbed in the proximal tubule and therefore these cells are not 
continuously exposed to glucose. In diabetic patients, the excess of filtered glucose often 
escapes reabsorption in the proximal tubule, allowing a significant amount of glucose in the 
tubular fluid that reaches the DCT. It is possible that the presence of glucose acting as a 
calcimimetic increases apical CaSR sensibility, enhancing NCC activity of thus NaCl 
reabsorption, which could help to explain the higher prevalence of hypertension in patients 
with diabetes
74
. These possibilities are speculative but can certainly be explored in future 
studies.    
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Figure Legends 
Fig. 1. CaSR activates NCC in a WNK4-dependent manner in X. laevis oocytes. A. The 
presence of none activated CaSR has no effect on WNK4 or WNK1-induced activation of NCC.
Functional expression assay shows the thiazide-sensitive Na
+
 uptake in groups of oocytes 
injected with NCC, NCC + hWNK4, NCC + WNK1D11 cRNA (black bars) or together with CaSR 
cRNA (grey bars), as stated. Uptake in oocytes injected with NCC cRNA alone was arbitrarily 
set to 100% and the corresponding groups were normalized accordingly.  **p<0.005 vs. NCC. 
B. Activation of CaSR with GdCl3 increased the activity of NCC only in the presence of WNK4.
Uptake was performed in control conditions (black bars) or after stimulation with GdCl3 80 
µM for 15 min. Each group in control conditions (black bar) was arbitrarily set to 100% and 
the corresponding group with GdCl3 was normalized accordingly (gray bars). ***p<0.0005 vs. 
its own control. Supplemental Figure 1 shows the same experiments but with data expressed 
as pmol/oocyte/h.
Fig. 2. CaSR phosphorylates SPAK in a WNK4-dependent manner in HEK-293 cells. A.
Representative immunoblot of cells transfected with hSPAK-GFP-HA, mWNK4-HA and hCaSR 
in different combinations as stated. The day before the experiment cells were serum-starved 
in the normal growth medium and left overnight. The next day, cells were stimulated with R-
568 (200 nM) for 30 min. B. Densitometric analysis of A. SPAK transfection alone in control 
conditions was arbitrarily set to 1 and the corresponding groups were normalized 
accordingly. Bars represent mean ± S.E.M, of at least 3 independent experiments. *p<0.05 
vs. control. C. Representative immunoblot showing two experiments of cells transected with 
empty vector (EMPTY), hSPAK-GFP-HA, mWNK4-HA and hCaSR and treated as in A. The WNK 
inhibitor WNK463 was added to the medium for 2 h on the day of the experiment to a final 
concentration of 4 µM. D. Densitometric analysis of C. SPAK in control conditions was 
arbitrarily set to 1 and the corresponding groups were normalized accordingly. Bars 
represent mean ± S.E.M, of at least 3 independent experiments. *p<0.05 vs. Control (no 
stimulation with R-568 and no WNK463). ***p<0.005 vs. R-568.   
Fig. 3. An activating mutation of CaSR phosphorylates SPAK and increases WNK4 
abundance. A. Representative immunoblot of HEK-293 cells transfected with mWNK4-HA, 
hCaSR WT and CaSR mutants with or without Klhl3 DNA (40 ng). For this set of experiments, 
cells were maintained in normal growth medium after transfection. B. Densitometric 
analysis of A. where the expression of WNK4 alone (WNK4) was set to 1 and the rest of the 
groups were normalized accordingly. Bars represent mean ± S.E.M, of at least 3 independent 
experiments.***p<0.0005 and **p<0.05 vs. WNK4. C. and D. Densitometric analysis where 
WNK4 (Control) without KLHL3 cotransfection (C.) or with KLHL3 (D.) were set to 1 and the 
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rest of the groups were normalized accordingly. Bars depict mean ± S.E.M, of at least 3 
independent experiments ***p<0.0005 vs. WNK4+KLHL3 (Control of D.).  
Fig. 4. CaSR promotes KLHL3 and WNK4 phosphorylation by PKC. A. Representative 
immunoblot of immunopurified KLHL3-Flag from HEK-293 cells transfected with KLHL3, WT 
hCaSR and CaSR mutants. Cells were maintained in normal growth medium after 
transfection. Graph depicts densitometric analysis of at least 3 independent experiments. 
KLHL3 immunopurified from transfection alone (Control) was set as 1 and the rest of the 
groups were normalized accordingly. Bars represent mean ± S.E.M. **p<0.005 vs. Control. B.
Representative image of immunopurified KLHL3-Flag from HEK-293 cells transfected with 
KLHL3, CaSR-E228K and treated with a PKC inhibitor (BIM). 4 µM of BIM was added to the 
normal growth medium and left overnight. The next day, cells were lysed and 
immunoblotted. Graph shows densitometric analysis of 3 experiments. Bars represent mean 
± S.E.M. *p<0.05 vs KLHL3 CaSR-E228K without BIM. C. Representative immunoblot of cells 
transfected with SPAK-GFP-HA, mWNK4-HA and WT hCaSR, serum-starved and stimulated 
with R-568 (200 nM) for 30 min. Lysates were blotted with the indicated antibodies. The 
graph depicts densitometric analysis. *p<0.05 vs. Control (no stimulation with R-568). D.
Cells were transfected with SPAK-GFP-HA, mWNK4-HA and WT hCaSR or the mutant 
mWNK45A, which has all PKC-phosphorylation sites mutated to alanines, and then 
stimulated as in C. The graph represents densitometric analysis of at least 3 independent 
experiments for the mWNK45A mutant. Bars are mean ± S.E.M. ***p<0.0005 vs. its own 
control (Data for SPAK-mWNK4-CaSR are shared with Figure 2 D). 
Fig. 5. CaSR promotes NCC phosphorylation in vivo. Animals were administered with vehicle 
or with R-568 3 µg/g of body weight through oral gavage. 3 h later, kidneys were harvested 
and processed for immunoblot. Each column of the representative immunoblot represents 
the kidneys from one animal. A and C. Representative immunoblot of the effect of oral R-
568 administration on NCC and NKCC2 phosphorylation, WNK4 abundance and 
phosphorylation in S64 in WT mice (Upper image). pS64/WNK4 1.00 vs. 1.3050, p=NS. E.
Immunofluorescent staining of kidney sections from WT mice treated with Vehicle or R-568. 
(Scale bars, 20 µm). F. Representative immunoblot of the effect of R-568 on NCC 
phosphorylation in SPAK knock-in mice (SPAK
243A/243A
). B., D. and G. Densitometric analysis 
of representative immunoblots. Bars represent mean ± S.E.M. *p<0.05 vs. Vehicle. 
Fig. 6. An acute furosemide treatment promotes NCC phosphorylation in vivo. Animals 
were administered with vehicle or with furosemide 15 mg/kg of body weight through IP 
injection. 3 h later, kidneys were harvested and processed for immunoblot. Each column of 
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the representative immunoblot represents the kidney from one animal. A. and C.
Representative immunoblots of the effect of the acute administration of furosemide on NCC 
phosphorylation, WNK4 abundance and phosphorylation in S64 in WT mice. pS64/WNK4 
1.00 vs. 1.53, p=NS. B. and D. Densitometric analysis of n=8 controls and n=7 furosemide 
administered mice. Bars represent mean ± S.E.M *p<0.05 vs. Vehicle. 
Fig. 7. CaSR promotes NCC phosphorylation ex vivo. A. Representative immunoblot of 
protein extracts from ex vivo perfused rat kidneys. The kidneys were perfused with 
physiological saline with vehicle or with R-568 at a rate of 0.60 µg/ml/min. Each column of 
the immunoblot represents one kidney. B. Bars represent mean ± S.E.M of the densitometric 
analysis of A. n=6 Vehicles and n=7 R-568. **p<0.005 vs. vehicle. *p<0.05 vs. vehicle. 
Fig. 8. Proposed model for CaSR effect on NCC. Increased extracellular Ca
2+
 leads to CaSR-
mediated inhibition of NKCC2 and ROMK, halting the transepithelial voltage difference that 
drags paracellular reabsorption of Ca
2+
 ions. Reduction in Ca
2+ 
reabsorption in the TALH 
causes increased NaCl and Ca
2+
 delivery to the distal nephron. In the DCT, integration of 
calcium and NaCl homeostasis by the CaSR must respond to prevent unwanted NaCl loss. We 
propose the existence of a mechanism in the DCT where apically expressed CaSR responds to 
increased intratubular Ca
2+
 concentration evoking a CaSR-Gq-PKC-WNK4 signaling 
transduction pathway that promotes NCC activation. 
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Supplemental Information
1. Supplemental Figures
Supplementary Fig. 1. CaSR activates NCC in a WNK4-dependent manner in X. laevis oocytes. A. The 
presence of none activated CaSR has no effect on WNK4 or WNK1-induced activation of NCC. Functional 
expression assay shows the thiazide-sensitive Na+ uptake (pmol/oocyte/h) in groups of oocytes injected with 
NCC, NCC + hWNK4, NCC + WNK1D11 cRNA (black bars) or together with CaSR cRNA (grey bars), as stated. 
**p<0.005 vs. NCC. ***p=0.0005 vs. NCC. ****p<0.0001 vs. NCC. B. Activation of CaSR with GdCl3 increased 
the activity of NCC only in the presence of WNK4. Uptake was performed in control conditions (black bars) 
or after stimulation with GdCl3 80 µM for 15 min (gray bars). **p<0.005 vs. its own control (NCC CaSR 
hWNK4 with no stimulation). 
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Supplementary Fig. 2. CaSR phosphorylates SPAK in a time- and dose-dependent manner in
HEK-293 cells. A and B. Representative immunoblots of time- and dose- curves of HEK-293 
cells transfected with SPAK-GFP-HA, mWNK4-HA and hCaSR. The day before the experiment, 
cells were serum-starved in a calcium free isotonic medium and left overnight. On the day 
of the experiment, cells were switched to an isotonic solution containing 0.75 mM CaCl2 + 
the indicated concentrations of R-568 for the indicated times. C. and D. Densitometric 
analyses are shown in the graphs below the representative immunoblot. Each point in the 
graphs depicts the mean  S.E.M of at least 3 independent experiments.
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2. Complete Methods
2.1. NCC functional experiments in X. laevis oocytes extended
The use of Xenopus laevis frogs was approved by the Animal Care and Use 
committee of our institution. Oocytes were surgically extracted from Tricaine 
(0.17%) anesthetized adult female Xenopus laevis frogs and incubated in Ca2+-
free ND96 medium (96 mM NaCl, 2 mM KCl, 1 mM MgCl2 and 5 mM HEPES, pH 
7.4) together with type B collagenase for 1.5 hours. After four washes with 
ND96 medium (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2 and 5 mM 
HEPES, pH 7.4) oocytes were incubated overnight at 16°C in ND96 medium, 
supplemented with 5 mg/100 ml gentamicin. The next day, oocytes were 
microinjected with 50 nl of H2O alone or containing 0.2-0.4 µg/µl of NCC, hCaSR, 
hWNK4, or hWNK1 cRNA in various combinations. Oocytes were then 
maintained at 16 C with daily changes of ND96 medium with gentamicin until 
the day of the experiment. cRNA for injection was transcribed in vitro from 
ĐDNA liŶearized at the ϯ’ eŶd usiŶg T7 RNA polyŵerase ŵMESSAGE kit 
(Ambion). All experimental data is based on a minimum of 3 independent 
experiments.
48 hours after microinjection, NCC transport assay was conducted following our 
protocol1-3 utilizing the radioactive tracer 22Na+ (Perkin Elmer Life Sciences). 
Briefly, 10-15 oocytes per well were pre-incubated for 15 minutes in a Cl--free 
ND96 medium (96 mM Na+ isethionate, 2mM K+ gluconate, 1.8 mM Ca2+
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gluconate, 1 mM Mg2+ gluconate and 5 mM HEPES, pH 7.4) containing 1mM 
ouabain, 100 µM amiloride, 100 µM bumetanide and in the presence or 
absence of 100 µM metolazone. Then, oocytes were transferred for uptake to 
a K+-free uptake medium (40 mM NaCl, 56 mM Na+ gluconate, 4 mM CaCl2, 1 
mM MgCl2 and 5 mM HEPES, pH 7.4) containing ouabain, amiloride, 
bumetanide, with or without metolazone and with 1 µCi of 22Na+ for 60 minutes
at 32 °C. At the end of the uptake period, oocytes were transferred to ice-cold 
radioactive-free uptake medium and washed five times to remove any excess 
of radioactive tracer from oocytes membrane. Oocytes were finally placed 
individually in plastic tubes containing SDS 1% to be lysed and for radioactive 
tracer determination with cintillation counting. For treatment with GdCl3, 
oocytes were pre-incubated for 15 minutes in the Cl--free ND96 medium, then 
transferred to wells with or without 80 µM of GdCl3 in the Cl
--free ND96 
medium for 15 minutes, then washed one time in the uptake medium and then 
transferred for uptake. 
2.2. Cell Culture and Transient Transfection Experiments
HEK-293 cells were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA, USA) and cultured at 37°C under 95% air and 5% CO2 in DMEM 
(11965-09ϮͿ ;DulďeĐĐo’s Modified Eagle’s ŵediuŵ, Life TeĐhŶologiesͿ 
containing 1.8 mM Ca2+ and supplemented with 10% FBS (Invitrogen) and 100 
U/ml penicillin and streptomycin (Invitrogen). These cells were transiently 
transfected with hCaSR, mWNK4-HA-FLAG, mWNK45A-HA5 and hSPAK-GFP-HA 
DNA. hCaSR-E228K and hCaSR185Q were generated in our own laboratories. 
Cells were transfected with lipofectamine 2000 (Life Technologies) following 
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ŵaŶufaĐturer’s instructions. For treatment with NPS R-568 (Tocris Biosciences), 
cells were serum-depleted overnight and then the drug was added before to 
the culture medium and incubated at 37°C for 30 min. For treatment with PKC 
inhibitor bisindolylmaleimide I (BIM) (Cell Signaling Technology), the drug was 
added to the culture medium and left overnight. For treatment with WNK463, 
the drug was added to the culture medium to a final concentration of 4 µM for 
2 h prior to the administration of NPS R-568. 
For the time- and dose-response curves in Supplementary Fig 1A and B, cells 
were fasted overnight in a Ca2+-free isotonic solution (135 mM NaCl, 5 mM KCl, 
0.5 mM MgCl2, 0.5 mM Na2SO4, 0.5 mM Na2HPO4, 15 mM HEPES, 25 mM 
glucose, pH 7.4). On the next day, cells were switched to an isotonic solution 
phosphate- and sulphate-free with calcium (135 mM NaCl, 5 mM KCl, 0.75 mM 
CaCl2, 1 mM MgCl2, 15 mM HEPES, 25 mM glucose, pH 7.4) with or without NPS 
R-568 (Tocris Biosciences) for the time and dose indicated before lysis.
2.3. Western Blot and Immunoprecipitation
48 hours after transfection, cells were lysed with a lysis buffer (50 mM Tris-HCl 
(pH 7.5), 1mM EGTA, 1 mM EDTA, 50 mM sodium fluoride, 5 mM sodium 
pyrophosphate, 1 mM sodium orthovanadate, 1% (wt/vol) Nonidet P-40 and 
0.27 M sucrose) containing protease inhibitors (Complete, Roche). Cells were 
then pelleted by centrifugation at 20,000 g for 12 minutes at 4°C and 
supernatants were recovered. Protein concentration was quantified by the BCA 
protein assay. 20 µg of cell lysate was prepared with Laemmli buffer 5X and 
separated by electrophoresis on 7.5% SDS-PAGE. Cell lysates (0.3-0.5 mg of 
protein) that were used for immunoprecipation were incubated with 10 µl of 
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agarose beads coated with anti-FLAG antibody (Sigma-Aldrich) at 4°C for 2 
hours. Beads were collected by centrifugation and washed two times with 500 
µl of IP buffer and one time with ice-cold PBS buffer. IP proteins were eluted 
with 20 µl of Laemmli buffer 2.5X at 95°C for 8 minutes and separated by 
electrophoresis on 7.5% SDS-PAGE. Proteins were electrotransferred onto 
PVDF membranes and immunoblotting was performed. Membranes were 
blocked for 1.5 hours in 10% (wt/vol) nonfat milk (BioRad) dissolved in Tris-
buffered saline (TBS)-Tween20. Incubation with primary selective antibodies 
was conducted overnight at 4°C and with secondary antibodies for 1 hour at 
room temperature. The following primary commercial HRP-conjugated 
antibodies were used: anti-Flag 1:5000 (Sigma-Aldrich), anti-HA 1:2500 (Sigma-
Aldrich), anti-beta-actin 1:2500 (Santa Cruz Biotechnology). Other commercial 
antibodies not HRP-conjugated were: monoclonal anti-CaSR 0.8 µl/ml (Sigma), 
pERK 1:4000 (Cell Signaling Technology) and pRRXS 1:2000 (Cell Signaling 
Technology). Polyclonal antibodies raised in sheep against NCC (S965B), 
phosphorylated NCC at threonines 45,50 and 55 (S995B), SPAK (S150C) and 
phosphorylated SPAK at serine 373 (S670BC). The concentrations used were 1-
3 µg/ml. These antibodies were produced at the Medical Research Council 
phosphorylation unit at Dundee University. The specificity of these antibodies 
has been extensively proven. The secondary antibodies were HRP-conjugated: 
anti-mouse 1:2000 (GE), anti-Rabbit 1:10000 (Sigma) and anti-Sheep 1:10000 
(Jackson). All antibodies were diluted in 5% (wt/vol) nonfat milk (BioRad) 
dissolved in TBS-Tween20. The immune reaction signal was detected by 
chemiluminescence using the Luminata Forte Western HRP substrate 
(Millipore).
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2.4. Animal studies
Animal studies were conducted in accordance with the Guide for the Care and 
Use of Laboratory Animals (National Academy Press, Washington DC, 1996) and 
were approved by the Animal Care and Use committee of our institution.
2.4.1 Mice Studies. The strains used were C57BL/6 for the WT mice and 
SPAK234A/243A for the SPAK knock-in mice. For every study performed, only adult 
male mice were used. Mice (12-16-week-old), were kept in cages with free 
access to food and water. For the R-568 experiment, on the day of the 
experiment, mice were andomly assigned to vehicle or drug-administered 
groups. The calcimimetic NPS R-568 (Tocris Biosciences) was dissolved in 10% 
cyclodextrin and was administered (3 µg/g of weight) by oral gavage. 3 hours 
later, kidneys were extracted under deep anesthesia and frozen in liquid 
nitrogen. Kidneys were homogenized using a lysis buffer (250 mM sucrose, 10 
mM triethanolamine, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 1 
mM sodium orthovanadate) supplemented with Complete tablets (Roche). 
Lysates were centrifuged 10,000 g for 10 minutes and supernatants with kidney 
protein extracts were recovered, quantified with a BCA assay and prepared for 
immunoblot.
For the furosemide (Sigma) experiment, an acute IP dose of 15 mg/kg was 
administered to C57BL/6 mice. 3 hours later, kidneys were extracted under 
deep anesthesia, frozen in liquid nitrogen and prepared for Western blot 
analysis.
2.4.2 Rat Kidney perfusion. The right kidney of male Wistar rats was mounted in 
the Langendorff system as previously described6,7 and perfused with vehicle 
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(physiological saline with 10% cyclodextrin) or the calcimimetic NPS R-568 
(Tocris Biosciences) at a rate of 0, 0.60 and 1.8 µg/ml/min9 , which had no effect 
on the perfusion pressure. After 30 minutes of perfusion, the kidney was 
manually separated into the cortex and medulla and the cortex was frozen in 
liquid nitrogen. Kidneys were homogenized using a lysis buffer (see Western 
Blot and Immunoprecipitation above). Lysates were centrifuged 10,000 g for 10 
minutes and supernatants with kidney protein extracts were recovered, 
quantified and prepared for immunoblot.
2.4.3 Immunofluorescence. Mice were anesthetized with pentobarbital (60 
mg/kg). One kidney was extracted for Western blot analysis, and the other 
kidney was perfused with approximately 5 ml of 4 % (wt/vol) paraformaldehyde 
in PBS. Kidney was then extracted, incubated in 4% (wt/vol) paraformaldehyde 
in PBS for at least 3 h, and then incubated in 30% (wt/vol) sucrose in PBS 
overnight at room temperature. The kidneys were mounted in OCT (Tissue-Tek) 
and 5 µm sections were prepared. The slides were kept at -80°C until 
immunostaining. For immunostaining, tissues were hydrated in TBS-tween 
0.1% and then incubated in blocking buffer for 1 h (3% (wt/vol) BSA in TBS-
tween 1%). Then, slides were incubated with primary and secondary antibodies 
dissolved in 1% BSA in TBS-tween 0.1%. The following antibodies were used: 
anti-NCC8 (1:100) and Alexa Fluor 488 (1:400) from Life Technologies. 
Page 43 of 46
ScholarOne support: 888-503-1050
Journal of the American Society of NEPHROLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
–
phosphorylated at the amino-terminal domain upon intracellular chloride 
depletion. J Biol Chem 281, 28755–28763 (2006).
3. Bazúa-Valenti, S. et al. The Effect of WNK4 on the Na+-Cl- Cotransporter Is 
Modulated by Intracellular Chloride. 26: J Am Soc Nephrol 1781–1786, 2015
4. López-Barradas, A. et al. Insulin and SGK1 reduce the function of 
Na+/monocarboxylate transporter 1 (SMCT1/SLC5A8). Am J Physiol Cell 
Physiol 311, C720–C734 (2016).
5. Castañeda-Bueno, M. et al. Phosphorylation by PKC and PKA regulate the 
kinase activity and downstream signaling of WNK4. Proc Natl Acad Sci USA
114, E879–E886 (2017).
6. Chávez-Canales, M. et al. Insulin increases the functional activity of the 
renal NaCl cotransporter. J Hypertens 31, 303–311 (2013).
7. Rojas-Vega, L. et al. Ovarian Hormones and Prolactin Increase the Renal 
NaCl Cotransporter Phosphorylation. Am J Physiol Renal Physiol 308,
ScholarOne support: 888-503-1050
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
–
7 (2009).  
ScholarOne support: 888-503-1050
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
The Calcium-sensing Receptor Increases Activity of the Renal 
NaCl Cotransporter Through the WNK4-SPAK Pathway 
RESULTSMETHODS
doi: 10.1681/ASN.2017111155 
CONCLUSION Activation of the CaSR induces NCC activation by a pathway that involves PKC-activation of the WNK4-
SPAK pathway. This mechanism has implications in the salt recovery in the DCT during TALH inhibition by extracellular calcium.   
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 Stimulation of the CaSR induces NCC activation in a WNK4 dependent manner  R-568 in mice induces activation of NCC and increased expression of WNK4  The effect of CaSR activation on WNK4 is mediated by PKC  In vitro study: oocytes and HEK293 cells transfected with NCC, CaSR, SPAK and 
WNK4, exposed to Gd3+ or R-568 and 
assessed for NCC or SPAK 
phosphorylaiton 
 In vivo study: Mice treated with oral 
administration of a single R-568 dose 
and assessed for NCC, NKCC2, and 
WNK4 expression and phosphorylation  
 In vivo study: SPAK-KI mice (T243A) 
treated with oral administration of a 
single R-568 dose and assessed for 
NCC expression and phosphorylation  
 Ex vivo perfusion: rat kidneys perfused 
ex vivo with R-568 and assessed for 
NCC expression and phosphorylation.  
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